06/03/2014 - 2:14pm

In an effort to spotlight the importance of early detection of memory problems, the Alzheimer's Foundation of America on Monday announced it is collaborating with Rite Aid to offer free, confidential memory screenings at all Rite Aid stores on June 4, from 10 a.m. to 2 p.m.

06/03/2014 - 1:56pm

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday presented the 2014 Nexus Award for Lifetime Achievement to David Moody, Jr., CEO of Mutual Wholesale Drug Co.

06/03/2014 - 1:24pm

Friendship cottage cheese on Tuesday announced a new collection of mix-in recipe ideas, which are ideal for even the most hectic schedules, the company said.

06/03/2014 - 1:11pm

Asana BioSciences, a research and development company specializing in the discovery and development of new chemical and biological entities, on Tuesday announced that it has acquired an early stage branded pharmaceutical discovery platform from Endo Pharmaceuticals.

06/03/2014 - 1:00pm

A new analysis from Avalere Health released Tuesday found that consumers in exchanges receiving federal assistance to reduce their out-of-pocket costs may experience inconsistent reductions in spending depending on the plan they choose.

06/03/2014 - 11:12am

Dollar General on Tuesday announced it will be bringing its brand of EDLP discounting to three new states next year — Oregon, Maine and Rhode Island.

06/03/2014 - 10:50am

Sandoz on Tuesday announced an agreement with Upsher-Smith to obtain exclusive U.S. distribution rights for its branded potassium chloride line of products, Klor-Con, and market them under the Sandoz name.

06/03/2014 - 10:26am

The Centers for Medicare and Medicaid Services has announced new timing to implement the Medicaid average manufacturer price-based federal upper limits for prescription medications, a move that has been applauded by the National Association of Chain Drug Stores. The FULs were expected to be finalized in July.

06/03/2014 - 10:10am

Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, on Tuesday announced that Teva has entered into a definitive agreement to acquire Labrys in a deal for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones.